Aktuellt
SENASTE
Redeye provides its initial take on Heliospectra’s Q1’23 report, stating that sales and order intake were weaker than our forecast. However, the outlook remains positive, and the cost base is well-contained. As a result, we anticipate only marginal adjustments to our near-term estimates and likely leave our fair value range intact.
LÄS MER
